Cellectar Biosciences, Inc. (CLRB) - Dilution Analysis

S-1/A filing: The filing is a registration statement for the resale of up to 51,998,413 shares of common stock by selling stockholders, including shares issuable upon the exercise of various warrants.

S-1 filing: This filing relates to the resale of up to 51,206,051 shares of common stock by selling stockholders, including shares issued in a private placement and shares issuable upon the exercise of various warrants.

10-Q filing | 4.2M shares outstanding

8-K filing: Cellectar Biosciences, Inc. entered into a securities purchase agreement to issue and sell shares of common stock and warrants in a registered direct offering and concurrent private placement, with gross proceeds expected to be approximately $35 million. ($35.0M proceeds)

10-Q filing | 3.2M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 2,096,188 shares of common stock by selling stockholders, issuable upon exercise of common stock purchase warrants.

10-Q filing | 1.8M shares outstanding

S-1/A filing: This is an S-1/A filing for an offering of up to 1,556,674 shares of common stock issuable upon exercise of warrants, Class A Units (one share of common stock and one common warrant) and Class B Units (one pre-funded warrant and one common warrant).

S-1 filing: The company is offering Class A Units, Class B Units, shares of common stock, Pre-Funded Warrants, Common Warrants and shares of common stock underlying the Pre-Funded Warrants and Common Warrants.

8-K filing: Cellectar Biosciences, Inc. entered into warrant exercise inducement offer letters for the immediate exercise of outstanding warrants to purchase 8,301,322 shares of common stock at a reduced exercise price of $0.3041 per share. ($2.53M proceeds)

10-Q filing | 46.1M shares outstanding

10-K filing | 46.1M shares outstanding

S-1 filing: The filing is an S-1 form regarding the resale of up to 19,221,348 shares of common stock by selling stockholders, issuable upon exercise of common stock purchase warrants.

10-Q filing | 39.8M shares outstanding

10-Q filing | 35.8M shares outstanding

8-K filing: Cellectar Biosciences, Inc. entered into warrant exercise inducement offer letters with certain holders of its Tranche B warrants, who agreed to exercise their Existing Warrants to purchase shares of Series E-4 Convertible Voting Preferred Stock which is convertible to 6,739,918 shares of the Company's common stock at a reduced price of $2.52 per share, in exchange for new warrants; the company received $19.4 million in gross proceeds. ($19.4M proceeds)

S-3 filing: Cellectar Biosciences, Inc. may offer and sell, from time to time, shares of common stock; shares of preferred stock; debt securities; warrants; rights to purchase common stock, preferred stock, debt securities or units; as well as units that include any of these securities up to $300,000,000.

10-Q filing | 33.2M shares outstanding

10-K filing | 9.4M shares outstanding

10-Q filing | 9.9M shares outstanding

S-3/A filing: Registration of 34,487,159 shares of common stock issuable upon conversion of preferred stock and warrants.

S-3 filing: This prospectus relates to the resale of up to 34,487,159 shares of common stock by the selling stockholders.

8-K filing: Cellectar Biosciences, Inc. completed a private placement offering of 1,225 shares of Series E-1 Convertible Voting Preferred Stock, Tranche A Warrants to acquire 2,205 shares of Series E-3 Convertible Voting Preferred Stock, and Tranche B Warrants to acquire 1,715 shares of Series E-4 Convertible Voting Preferred Stock for an aggregate offering price of $24.5 million. ($24.5M proceeds)

10-Q filing | 9.7M shares outstanding

10-Q filing | 9.7M shares outstanding

10-K filing | 9.7M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 7,027,043 shares of common stock issuable upon the exercise of outstanding warrants.

10-Q filing | 6.1M shares outstanding

10-Q filing | 6.1M shares outstanding

10-Q filing | 61.1M shares outstanding

10-K filing | 45.4M shares outstanding

10-Q filing | 59.9M shares outstanding

10-Q filing | 55.3M shares outstanding

10-Q filing | 52.7M shares outstanding

10-K filing | 50.5M shares outstanding

S-3 filing: This is an S-3 filing for the resale of common stock issuable upon conversion of Series D Preferred Stock and also covers the sale of common stock to underwriters.

8-K filing: Cellectar Biosciences, Inc. executed an underwriting agreement to sell 18,148,136 shares of common stock at $1.35 per share and a securities purchase agreement to sell 1,518.5180 shares of Series D convertible preferred stock at $13,500 per share.

10-Q filing | 26.8M shares outstanding

S-3 filing: Cellectar Biosciences, Inc. may offer to sell common stock, preferred stock, and subscription rights, with an aggregate initial offering price not to exceed $100,000,000.

10-Q filing | 26.6M shares outstanding

8-K filing: Cellectar Biosciences, Inc. sold 14,601,628 shares of common stock, 2,789,700 pre-funded warrants, and 8,694,664 Series H warrants in a public offering, with net proceeds of approximately $18.2 million.

S-1/A filing: This is an S-1/A filing for offering 11,904,762 shares of common stock, pre-funded warrants, and warrants to purchase 5,952,381 shares of common stock.

S-1 filing: This S-1 filing describes an offering of common stock, pre-funded warrants to purchase common stock, and warrants to purchase common stock, along with associated Series H Warrants, with Oppenheimer & Co. acting as the sole book-running manager.

10-Q filing | 9.4M shares outstanding

10-K filing | 9.4M shares outstanding